The FDA has expanded the approval of Dextenza (dexamethasone ophthalmic insert) to include pediatric treatment.

YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, ...

The Food and Drug Administration (FDA) has expanded the approval of Dextenza ® (dexamethasone ophthalmic ... with prednisolone acetate suspension eye drops as a treatment for postoperative ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily ...

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and ...

About OCS-01 eye drops and the OPTIREACH® technology Leveraging Oculis’ proprietary technology, OCS-01 is an OPTIREACH® formulation of high concentration dexamethasone eye drop. It is being ...

Leveraging Oculis' proprietary technology, OCS-01 is an OPTIREACH® formulation of high concentration dexamethasone eye drop ... technology addresses the main limitations of conventional eye drops by ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

OCS-01, leveraging Oculis' proprietary OPTIREACH® technology, is a high-concentration dexamethasone eye drop that aims to offer a non-invasive treatment alternative for DME, a condition that ...